TB-500 (Thymosin Beta-4): Tissue Regeneration and Recovery — Scientific Guide
TB-500 is the active synthetic fragment of Thymosin Beta-4, a ubiquitous protein involved in actin regulation, angiogenesis, and cell migration. It is one of the most studied research peptides for soft tissue repair.
Thymosin Beta-4 and its active fragment
La Thymosin Beta-4 (Tβ4) is a 43-amino-acid protein present in virtually all cells of eukaryotic organisms. It plays a fundamental role in the G-actin sequestration (maintenance of the pool of unpolymerized actin) and in the dynamic regulation of the cytoskeleton.
Le TB-500 corresponds to fragment 17-23 of Thymosin Beta-4 (sequence: LKKTETQ), identified as the minimal active fragment responsible for the cell migration promotion and tissue repair properties. It is this fragment that concentrates most of the biological activity of the parent protein in a much more stable heptapeptide.
TB-500 (a fragment of Thymosin Beta-4) is often confused with Thymosin Alpha-1 (Tα1, Zadaxin), which is an entirely separate molecule with immunomodulatory properties. These are two different peptides with distinct mechanisms and application areas.
Mechanisms of action
Actin regulation and cell migration
The central mechanism of TB-500 is binding to G-actin (non-polymerized monomeric actin). By modulating the availability of G-actin, it regulates the actin filament polymerization, an essential process for:
- Cell migration (motility of fibroblasts, keratinocytes, endothelial cells)
- The formation of lamellipodia during wound healing
- Cytoskeletal reorganization during the response to growth factors
Angiogenesis — formation of new blood vessels
TB-500 stimulates angiogenesis (neovascularization) through several mechanisms:
- Stimulation of vascular endothelial cell migration and proliferation
- Upregulation of VEGF (Vascular Endothelial Growth Factor)
- Activation of the PI3K/Akt pathway in endothelial cells
- Formation of vascular tubules in in vitro models (Matrigel assay)
This pro-angiogenic property is of particular interest for wound healing research, as vascularization of the injury site is the critical limiting step in tissue repair.
Anti-inflammatory effects
Preclinical studies document a reduction in pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissue injury models with TB-500 administration, via NF-κB modulation.
Preclinical data — main studies
| Study model | Observed effect | Administrative route |
|---|---|---|
| Tendon injury (rat) | ↑ Repair speed, ↑ Tensile strength | Systemic + local |
| Cardiac lesion (mouse) | Reduction of the infarct zone, increased angiogenesis | Systemic |
| Skin wound (rat) | Accelerated closure, neovascularization | Topical + systemic |
| Corneal lesion (rat) | Accelerated re-epithelialization | Local (eye drops) |
| Spinal cord injury | Partial improvement in motor skills | Systemic |
| Liver fibrosis (rat) | Fibrosis reduction, hepatocyte regeneration | Systemic |
Cardiac data — adult heart research
One of the most interesting findings about Tβ4 concerns its role in embryonic cardiogenesis and its ability to activate quiescent cardiac progenitor cells in the adult heart. Studies published in Nature (Smart et al., 2011) showed that Tβ4 could reactivate the embryonic epicardium and stimulate the formation of new cardiomyocytes after infarction in mice.
TB-500 Technical Specifications
| Property | Value |
|---|---|
| Sequence (active fragment) | Ac-LKKTETQ-NH2 (variants depending on manufacturer) |
| Molecular mass | ~888 Da (fragment) / ~4,964 Da (full Tβ4) |
| Solubility | Excellent in water — hydrophilic peptide |
| Recommended solvent | Bacteriostatic Water USP |
| Freeze-dried preservation | 12-24 months at -20°C, 6-12 months at 2-8°C |
| Reconstructed conservation | 28 days at 2-8°C (water tank) |
BPC-157 + TB-500: association in research
In many tissue repair research protocols, BPC-157 and TB-500 are studied in combination. The scientific rationale is based on their complementary mechanisms:
BPC-157
- NO system modulation
- Gastric protection
- EGF-R upregulation
- Stability in gastric solution
- Tendon fibroblasts
TB-500
- Actin G regulation
- Angiogenesis (VEGF)
- Cell migration
- Cardioprotection
- Endothelial cells
Limitations and state of research
As with BPC-157, the data on TB-500 are almost exclusively preclinical (rodents, cell models):
- Lack of published large-scale randomized clinical trials
- Thymosin Beta-4 (not the TB-500 fragment) is the subject of a clinical program at RegeneRx for corneal repair and chronic wounds — with mixed results.
- Open questions regarding the extrapolation of effective doses in rodents to humans
- Pro-angiogenic mechanisms theoretically to be monitored in neoplastic contexts
TB-500 research available at MyPeptide
Certified HPLC 99%+ with Janoshik COA. Available in 5 mg, 10 mg, and 20 mg strengths. Ships from the EU in 48-72 hours.
🧪 Research Peptides — Europe Delivery
≥99% Purity HPLC certified by Janoshik · COA available per batch · Discreet shipping 48-72h
🇫🇷 Retarturate France ·
🇧🇪 Belgium ·
🇩🇪 Germany ·
🇪🇸 Spain ·
🇮🇹 Italy
🇫🇷 GHK-Cu France ·
🇧🇪 Belgium ·
🇩🇪 Germany ·
🇪🇸 Spain ·
→ All countries
📚 Scientific reference:
Goldstein AL et al. “Thymosin beta-4: from bench to bedside. » Ann N Y Acad Sci. 2012.
PubMed PMID:22260244 →